|
KMID : 1039120200090010001
|
|
Clinical and Experimental Vaccine Research
2020 Volume.9 No. 1 p.1 ~ p.7
|
|
|
Hepatitis B vaccination and immunotherapies: an update
|
|
Stasi Cristina
Silvestri Caterina
Voller Fabio
|
|
|
Abstract
|
|
|
|
World Health Organization (WHO) estimates that 257 million people were living with chronic hepatitis B virus (HBV) infection. Highest HBV prevalence was found in the WHO Western Pacific Region (6.2%) and in the WHO African Region (6.1%). The HBV vaccine is the best protection against chronic HBV infection and its complications. Globally, routine infant immunization against HBV has increased with an estimated coverage of 84% in 2017. Nevertheless, in many countries further efforts are needed to implement this coverage and ensure national immunization programs for people at major risk for HBV infection. Therapeutic vaccination in chronic HBV infected patients can cause anti-HBV immune responses able to remove and/or cure infected hepatocytes. It shows promising results in murine model and human trials, but these results need to be consolidated by further multicenter clinical studies. In particular, the efficacy of therapeutic vaccine seems to improve by combination therapies.
|
|
|
KEYWORD
|
|
|
Hepatitis B virus infection, Vaccination, Therapeutic vaccine, Chronic hepatitis B
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|